Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients
Objectives: Sorafenib is the standard first-line treatment for HCC. No sufficient data exists regarding its efficacy in the Egyptian population being a costly medication that is not endorsed by insurance and hence is not used in most institutions. This study aimed to evaluate the overall survival [O...
Main Authors: | Noha Salah El Baghdady, Lamia Elwakeel, Mahmoud Ellithy, Nawal Hussein, Sara Shahin, Abdel Rahman El Naggar |
---|---|
Format: | Article |
Language: | English |
Published: |
Ain Shams University
2020-12-01
|
Series: | Archives of Pharmaceutical Sciences Ain Shams University |
Subjects: | |
Online Access: | https://aps.journals.ekb.eg/article_135136.html |
Similar Items
-
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01) -
Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
by: Qinqin Liu, et al.
Published: (2021-10-01) -
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01) -
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
by: Guilherme Nader Marta, et al.
Published: (2021-01-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)